Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage?Citation formats

Standard

Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage? / Hayton, C; Craig, C; Chaudhuri, N.

In: Journal of Thoracic Disease, 01.02.2019.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{05ea751287b7475c802277807601e9b6,
title = "Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage?",
abstract = "Despite progress in the therapeutic management of idiopathic pulmonary fibrosis (IPF) in the last decade, prognosis remains poor (1). This is particularly true of patients with severe disease, with 3-year mortality predicted at 76.8% for patients with advanced disease (2). Therapeutic trials in IPF typically exclude such patients which can subsequently have a significant impact on drug availability in the clinical setting. There is a desperate unmet need for treatment options in this advanced disease cohort.",
author = "C Hayton and C Craig and N Chaudhuri",
year = "2019",
month = feb,
day = "1",
doi = "10.21037/jtd.2018.12.33",
language = "English",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company",

}

RIS

TY - JOUR

T1 - Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage?

AU - Hayton, C

AU - Craig, C

AU - Chaudhuri, N

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Despite progress in the therapeutic management of idiopathic pulmonary fibrosis (IPF) in the last decade, prognosis remains poor (1). This is particularly true of patients with severe disease, with 3-year mortality predicted at 76.8% for patients with advanced disease (2). Therapeutic trials in IPF typically exclude such patients which can subsequently have a significant impact on drug availability in the clinical setting. There is a desperate unmet need for treatment options in this advanced disease cohort.

AB - Despite progress in the therapeutic management of idiopathic pulmonary fibrosis (IPF) in the last decade, prognosis remains poor (1). This is particularly true of patients with severe disease, with 3-year mortality predicted at 76.8% for patients with advanced disease (2). Therapeutic trials in IPF typically exclude such patients which can subsequently have a significant impact on drug availability in the clinical setting. There is a desperate unmet need for treatment options in this advanced disease cohort.

UR - http://europepmc.org/abstract/med/30962967

U2 - 10.21037/jtd.2018.12.33

DO - 10.21037/jtd.2018.12.33

M3 - Article

C2 - 30962967

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

ER -